Search ResultsShowing Results for 'Ras signaling'
Significance of Ras Signaling in Cancer and Strategies for its Control
H-Ras, K-Ras, and N-Ras are the main members of Ras superfamily, which bind small molecules GTP and GDP interchangeably and can hydrolyze GTP to GDP. The Ras superfamily consists of more than 150 proteins and these can be classified under at least five sub-families viz: the Ras, Rab, Rho, Ran, and Arf families.1 Ras oncoproteins […]
Investigating KRASG12C inhibitors: How might they improve outcomes for patients with solid tumours?
Prof. Tony Mok discusses the role of KRAS mutations in solid tumours and the impact of KRASG12C inhibitors on patient outcomes.
- Describe the role of KRAS in tumourigenesis and the implications of the KRASG12C mutation for patients with solid tumours
- Evaluate the efficacy and safety of KRASG12C inhibitors in advanced and metastatic KRAS-mutated solid tumours
- Formulate strategies to overcome intrinsic or acquired resistance to KRASG12C-directed therapies
New Molecular Targets in Lung Adenocarcinoma
Annually, 1.3 million cases of NSCLC occur.1 Despite smoking being the most important environmental causative factor for lung cancer, 10% of lung cancers occur in never-smokers, thus emphasizing the importance of genetic factors.2 Detection methods for genomic alterations include array-based profiling, targeted sequencing, and whole-genome sequencing. The following driver genetic alterations and respective frequencies occur […]
Precision Medicine in Metastatic Colorectal Cancer—Finding and Hitting the Right Targets
In 2020, an estimated 147,950 patients will be diagnosed with colorectal cancer (CRC) in the USA, with 53,200 deaths expected.1 While many patients with CRC are cured, metastatic CRC (mCRC) is still a prevalent disease, and systemic therapy options have markedly improved outcomes in patients with unresectable metastatic disease in the last several decades. Cytotoxic […]
New Molecular Targets In Non-Small Cell Lung Cancer: Highlights of the 2019 World Conference on Lung Cancer
Advances in understanding of the molecular processes underlying non-small cell lung cancer (NSCLC) have led to the identification of several specific targets for therapeutic agents. To date, the most beneficial therapies targeting gene rearrangements are those that target the ALK, EGFR and BRAF mutations. However, these alterations are present only in a minority of patients […]
Primary Tumor Location Implications on Biological Therapy in Metastatic Colorectal Cancer
Several studies have shown a survival advantage with the addition of anti-epidermal growth factor receptor (anti-EGFR) therapy to chemotherapy in molecularly selected patients with advanced colorectal cancer. The Panitumumab Randomized trial in combination with chemotherapy for Metastatic colorectal cancer to determine Efficacy (PRIME) clinical trial investigated the addition of panitumumab to folinic acid, fluorouracil, and […]
Circulating Tumor DNA in Colorectal Cancer—From Concept to Clinic
Colorectal cancer (CRC) is the third most common cancer worldwide and the second most common cause of cancer-related death,1 with its incidence predicted to continue to rise significantly in the future.2 With the evolution of personalized medicine, genomic profiling is crucial for treatment and monitoring of individuals’ cancer. The increasing availability of novel molecular-targeted therapy […]
BRAFV600E as a Therapeutic Target in Colorectal Cancer
Colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer deaths in the developed world,1,2 with an estimated 149,000 new cases and 50,000 deaths each year in the US.3 Considerable progress has been achieved in the systemic treatment of colorectal cancer over the last decade with the incorporation of […]
Improving Outcomes in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDA) is predicted to beat colon cancer in terms of total cancer-related deaths in the USA by this year (2020).1 Given this projected burden of disease, efforts in understanding and developing new treatments for PDA are paramount. In this review, we will summarize the molecular characteristics and mutations thought to be involved with […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!